/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Hoth Therapeutics Inc Share Price Today: Live Updates & Key Insights

Hoth Therapeutics Inc share price today is $0.9146, up -0.95%. The stock opened at $0.93 against the previous close of $0.9234, with an intraday high of $0.9393 and low of $0.8816.

Hoth Therapeutics Inc Share Price Chart

style
pb-0

Hoth Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Hoth Therapeutics Inc Share Price Performance

$0.9146 -0.0095(-0.95%) HOTH at 23 Mar 2026 01:29 PM Biotechnology
Lowest Today 0.8816
Highest Today 0.9393
Today’s Open 0.93
Prev. Close 0.9234
52 Week High 2.12
52 Week Low 0.66
Day’s Range: Low 0.8816 High 0.9393
52-Week Range: Low 0.66 High 2.12
1 day return -
1 Week return -14.06
1 month return -11.96
3 month return -19.09
6 month return -53.71
1 year return -14.47
3 year return -56.4
5 year return -98.35
10 year return -

Hoth Therapeutics Inc Institutional Holdings

Vanguard Group Inc 1.38

Geode Capital Management, LLC 1.17

Vanguard Institutional Extnd Mkt Idx Tr 0.84

Virtu Financial LLC 0.73

UBS Group AG 0.61

Fidelity Extended Market Index 0.57

State Street Corp 0.41

Susquehanna International Group, LLP 0.40

Northern Trust Corp 0.27

Renaissance Technologies Corp 0.22

Fidelity Nasdaq Composite Index 0.20

NT Ext Equity Mkt Idx Fd - NL 0.17

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.13

Lido Advisors, LLC 0.13

Spartan Extended Market Index Pool F 0.12

Jane Street Group LLC 0.11

TWO SIGMA SECURITIES, LLC 0.11

Fidelity Series Total Market Index 0.11

Fidelity Total Market Index 0.10

Northern Trust Extended Eq Market Idx 0.10

NT Ext Equity Mkt Idx Fd - L 0.10

Citigroup Inc 0.07

Spartan Total Market Index Pool G 0.07

Morgan Stanley - Brokerage Accounts 0.07

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.04

Advisor Group Holdings, Inc. 0.02

Tower Research Capital LLC 0.01

State St US Extended Mkt Indx NL Cl C 0.01

NT US Market Cap Idx Fd - L 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

SSgA U.S. Total Market Index Strategy 0.00

Federation des caisses Desjardins du Quebec 0.00

Royal Bank of Canada 0.00

Bank of America Corp 0.00

IFP Advisors, LLC 0.00

Northern Trust Wilshire 5000 0.00

Hoth Therapeutics Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Hoth Therapeutics Inc Fundamentals

Market Cap 14.19 M

PB Ratio 1.7141

PE Ratio 0.0

Enterprise Value 6.28 M

Total Assets 7.71 M

Volume 230909

Hoth Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:-66834 -0.1M, FY21:-46871000 -46.9M, FY20:-25871 -0.0M, FY19:-31622 -0.0M

Annual Net worth FY23:-9621743 -9.6M, FY22:-11677362 -11.7M, FY21:-14313705 -14.3M, FY20:-7197816 -7.2M, FY19:-7694275 -7.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:-4354 -0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-4105800 -4.1M, Q2/2025:-2199476 -2.2M, Q1/2025:-3475836 -3.5M, Q3/2024:-2132053 -2.1M, Q2/2024:-1632474 -1.6M

About Hoth Therapeutics Inc & investment objective

Company Information Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.

Organisation Biotechnology

Employees 2

Industry Biotechnology

CEO Mr. Robb Knie

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Hoth Therapeutics Inc FAQs

What is the share price of Hoth Therapeutics Inc today?

The current share price of Hoth Therapeutics Inc is $0.9146.

Can I buy Hoth Therapeutics Inc shares in India?

Yes, Indian investors can buy Hoth Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Hoth Therapeutics Inc shares in India?

You can easily invest in Hoth Therapeutics Inc shares from India by:

Can I buy fractional shares of Hoth Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Hoth Therapeutics Inc?

Hoth Therapeutics Inc has a market cap of $14.19 M.

In which sector does Hoth Therapeutics Inc belong?

Hoth Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Hoth Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Hoth Therapeutics Inc?

The PE ratio of Hoth Therapeutics Inc is N/A and the PB ratio is 1.71.